August J. MorettiDepomed, Inc.510.744.8000SOURCE Depomed, Inc.
A review of data produced by BoardEx reveals that many big and small activist-targeted corporate boards feature young directors in their early-to-mid 30s who work for insurgent fund managers
The company's new CEO tells analysts it continues to believe the novel painkiller Nucynta can be a blockbuster.
Depomed unveiled steps the company is taking to shore itself up.
Here are Wednesday's top research calls, including downgrades for Allergan and General Dynamics, and upgrades for Coach and Occidental Petroleum.